Jennifer Lachey
Directeur Technique/Scientifique/R&D chez KEROS THERAPEUTICS, INC.
Postes actifs de Jennifer Lachey
Sociétés | Poste | Début | Fin |
---|---|---|---|
KEROS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/06/2019 | - |
Corporate Officer/Principal | 01/07/2016 | 01/06/2019 |
Historique de carrière de Jennifer Lachey
Anciens postes connus de Jennifer Lachey
Sociétés | Poste | Début | Fin |
---|---|---|---|
SERES THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/03/2015 | 01/07/2016 |
EMBER THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2012 | 01/01/2015 |
ACCELERON PHARMA INC. | Corporate Officer/Principal | 01/01/2008 | 01/07/2012 |
Formation de Jennifer Lachey
Indiana University | Undergraduate Degree |
University of Cincinnati (Ohio) | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Opérationnelle
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 1 |
Director/Board Member | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
KEROS THERAPEUTICS, INC. | Health Technology |
SERES THERAPEUTICS, INC. | Health Technology |
EMBER THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
- Bourse
- Insiders
- Jennifer Lachey
- Expérience